Anti-inflammatory activity of natural stilbenoids: A review

Pharmacological Research

Volumn 124, Issue , 2017, Pages 126-145

  Dvorakova, Marcela ^a   Landa, Premysl ^a  

^a INSTITUTE OF EXPERIMENTAL BOTANY   (Czech Republic)

Author keywords

Bioavailability; Encapsulation; Inflammation; Metabolites; Multi targeted therapy; Natural stilbenes

Indexed keywords

3,5,4' TRIMETHOXYSTILBENE; 4 O METHYLPINOSYLVIC ACID; AMPELOPSIN C; AMPELOPSIN E; CAJANINSTILBENE ACID; DESOXYRHAPONTIGENIN; GNETOL; NATURAL PRODUCT; OXYRESVERATROL; PICEATANNOL; PINOSYLVIN; PINOSYLVIN MONOMETHYL ETHER; POLYPHENOL; PTEROSTILBENE; RESVERATROL; RHAPONTIGENIN; STILBENOID; UNCLASSIFIED DRUG; VINIFERIN; VITISIN A; VITISIN B; ANTIINFLAMMATORY AGENT; STILBENE DERIVATIVE;

ANTIINFLAMMATORY ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; HUMAN; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL;

ANIMALS; ANTI-INFLAMMATORY AGENTS; HUMANS; STILBENES;

EID: 85027706266     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2017.08.002     Document Type: Review

References (193)

1. Newton, K., Dixit, V.M., Signaling in innate immunity and inflammation. Cold Spring Harb. Perspect. Biol., 4, 2012, a006049.
2. Poulose, S.M., Thangthaeng, N., Miller, M.G., Shukitt-Hale, B., Effects of pterostilbene and resveratrol on brain and behavior. Neurochem. Int. 89 (2015), 227–233.
3. Choi, R.J., Chun, J., Khan, S., Kim, Y.S., Desoxyrhapontigenin, a potent anti-inflammatory phytochemical, inhibits LPS-induced inflammatory responses via suppressing NF-κB and MAPK pathways in RAW 264.7 cells. Int. Immunopharmacol. 18 (2014), 182–190.
4. Jeong, S.O., Son, Y., Lee, J.H., Cheong, Y.K., Park, S.H., Chung, H.T., Pae, H.O., Resveratrol analog piceatannol restores the palmitic acid-induced impairment of insulin signaling and production of endothelial nitric oxide via activation of anti-inflammatory and antioxidative heme oxygenase-1 in human endothelial cells. Mol. Med. Rep. 12 (2015), 937–944.
5. Lin, Y.J., Ding, Y., Wu, J., Ning, B.T., Pterostilbene as treatment for severe acute pancreatitis. Genet. Mol. Res., 15, 2016, 15038330.
6. Hou, Y., Li, N., Xie, G.B., Wang, J., Yuan, Q., Jia, C.C., Liu, X., Li, G.X., Tang, Y.Z., Wang, B., Pterostilbene exerts anti-neuroinflammatory effect on lipopolysaccharide-activated microglia via inhibition of MAPK signalling pathways. J. Funct. Food. 19 (2015), 676–687.
7. Simmons, D.L., What makes a good anti-inflammatory drug target?. Drug. Discov. Today 11 (2006), 210–219.
8. Nile, S.H., Park, S.W., Optimized methods for in vitro and in vivo anti-inflammatory assays and its applications in herbal and synthetic drug analysis. Mini Rev. Med. Chem. 13 (2013), 95–100.
9. Lewis, A.J., Manning, A.M., New targets for anti-inflammatory drugs. Curr. Opin. Chem. Biol. 3 (1999), 489–494.
10. Tambuwala, M.M., Natural nuclear factor kappa beta inhibitors: safe therapeutic options for inflammatory bowel disease. Inflamm. Bowel. Dis. 22 (2016), 719–723.
11. Ko, Y.J., Kim, H.H., Kim, E.J., Katakura, Y., Lee, W.S., Kim, G.S., Ryu, C.H., Piceatannol inhibits mast cell-mediated allergic inflammation. Int. J. Mol. Med. 31 (2013), 951–958.
12. Santini, A., Tenore, G.C., Novellino, E., Nutraceuticals A paradigm of proactive medicine. Eur. J. Pharm. Sci. 96 (2017), 53–61.
13. Shahpiri, Z., Bahramsoltani, R., Hosein Farzaei, M., Farzaei, F., Rahimi, R., Phytochemicals as future drugs for Parkinson's disease: a comprehensive review. Rev. Neurosci. 27 (2016), 651–668.
14. Wegener, T., Lupke, N.P., Treatment of patients with arthrosis of hip or knee with an aqueous extract of devil's claw (Harpagophytum procumbens DC.). Phytother. Res. 17 (2003), 1165–1172.
15. Badri, W., Miladi, K., Nazari, Q.A., Greige-Gerges, H., Fessi, H., Elaissari, A., Encapsulation of NSAIDs for inflammation management: overview progress, challenges and prospects. Int. J. Pharm. 515 (2016), 757–773.
16. Piotrowska, H., Kucinska, M., Murias, M., Biological activity of piceatannol: leaving the shadow of resveratrol. Mutat. Res. 750 (2012), 60–82.
17. Wang, K.T., Chen, L.G., Tseng, S.H., Huang, J.S., Hsieh, M.S., Wang, C.C., Anti-inflammatory effects of resveratrol and oligostilbenes from Vitis thunbergii var taiwaniana against lipopolysaccharide-induced arthritis. J. Agric. Food. Chem. 59 (2011), 3649–3656.
18. Ishihata, A., Maruki-Uchida, H., Gotoh, N., Kanno, S., Aso, Y., Togashi, S., Sai, M., Ito, T., Katano, Y., Vascular- and hepato-protective effects of passion fruit seed extract containing piceatannol in chronic high-fat diet-fed rats. Food. Funct. 7 (2016), 4075–4081.
19. Seyed, M.A., Jantan, I., Bukhari, S.N., Vijayaraghavan, K., A comprehensive review on the chemotherapeutic potential of piceatannol for cancer treatment, with mechanistic insights. J. Agric. Food. Chem. 64 (2016), 725–737.
20. Neves, A.R., Lúcio, M., Lima, J.L.C., Reis, S., Resveratrol in medicinal chemistry: a critical review of its pharmacokinetics drug-delivery, and membrane interactions. Curr. Med. Chem. 19 (2012), 1663–1681.
21. Rivière, C., Pawlus, A.D., Mérillon, J.M., Natural stilbenoids: distribution in the plant kingdom and chemotaxonomic interest in Vitaceae. Nat. Prod. Rep. 29 (2012), 1317–1333.
22. Fremont, L., Biological effects of resveratrol. Life Sci. 66 (2000), 663–673.
23. Zykova, T.A., Zhu, F., Zhai, X., Ma, W.Y., Ermakova, S.P., Lee, K.W., Bode, A.M., Dong, Z., Resveratrol directly targets COX-2 to inhibit carcinogenesis. Mol. Carcinog. 47 (2008), 797–805.
24. Khairullin, V.R., Mukhametov, A.D., Ya Gerchikov, A., Tarasov, G.P., Garifullina, G.G., Tyurina, L.A., Zarudii, F.S., Computer design of trans-stilbene derivatives with pronounced anti-inflammatory activity and low toxicity. Pharm. Chem. J. 43 (2009), 463–467.
25. Szaefer, H., Cichocki, M., Krajka-Kuźniak, V., Stefański, T., Sobiak, S., Licznerska, B., Baer-Dubowska, W., The effect of resveratrol and its methylthio-derivatives on NF-κB and AP-1 signaling pathways in HaCaT keratinocytes. Pharmacol. Rep. 66 (2014), 732–740.
26. Subbaramaiah, K., Chung, W.J., Michaluart, P., Telang, N., Tanabe, T., Inoue, H., Jang, M., Pezzuto, J.M., Dannenberg, A.J., Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J. Biol. Chem. 273 (1998), 21875–21882.
27. Martinez, J., Moreno, J.J., Effect of resveratrol a natural polyphenolic compound, on reactive oxygen species and prostaglandin production. Biochem. Pharmacol. 59 (2000), 865–870.
28. Shakibaei, M., Csaki, S., Mobasheri, A., Resveratrol suppresses interleukin-1β-induced inflammatory signaling and apoptosis in human articular chondrocytes: potential for use as a novel nutraceutical for the treatment of osteoarthritis. Biochem. Pharmacol. 76 (2008), 1426–1439.
29. Jang, M., Cai, L., Udeani, G.O., Slowing, K.V., Thomas, C.F., Beecher, C.W., Fong, H.H., Farnsworth, N.R., Kinghorn, A.D., Mehta, R.G., Moon, R.C., Pezzuto, J.M., Cancer chemopreventive activity of resveratrol: a natural product derived from grapes. Science 275 (1997), 218–220.
30. Szewczuk, L.M., Forti, L., Stivala, L.A., Penning, T.M., Resveratrol is a peroxidase-mediated inactivator of COX-1 but not COX-2: a mechanistic approach to the design of COX-1 selective agents. J. Biol. Chem. 279 (2004), 22727–22737.
31. Martín, A.R., Villegas, I., La Casa, C., e la Lastra, C.A., Resveratrol, a polyphenol found in grapes, suppresses oxidative damage and stimulates apoptosis during early colonic inflammation in rats. Biochem. Pharmacol. 67 (2004), 1399–1410.
32. Kundu, J.K., Shin, Y.K., Kim, S.H., Surh, Y.J., Resveratrol inhibits phorbol ester-induced expression of COX-2 and activation of NF-κB in mouse skin by blocking IκB kinase activity. Carcinogenesis 27 (2006), 1465–1474.
33. Larrosa, M., Yañéz-Gascón, M.J., Selma, M.V., González-Sarrías, A., Toti, S., Cerón, J.J., Tomás-Barberán, F., Dolara, P., Espín, J.C., Effect of a low dose of dietary resveratrol on colon microbiota: inflammation and tissue damage in a DSS-induced colitis rat model. J. Agric. Food Chem. 57 (2009), 2211–2220.
34. Singh, U.P., Singh, N.P., Singh, B., Hofseth, L.J., Price, R.L., Nagarkatti, M., Nagarkatti, P.S., Resveratrol (trans-3,5, 4’-trihydroxystilbene) induces silent mating type information regulation-1 and down-regulates nuclear transcription factor-κB activation to abrogate dextran sulfate sodium-induced colitis. J. Pharmacol. Exp. Ther. 332 (2010), 829–839.
35. Sánchez-Fidalgo, S., Cárdeno, A., Villegas, I., Talero, E., de la Lastra, C.A., Dietary supplementation of resveratrol attenuates chronic colonic inflammation in mice. Eur. J. Pharmacol. 633 (2010), 78–84.
36. Jin, F., Wu, Q., Lu, Y.F., Gong, Q.H., Shi, J.S., Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats. Eur. J. Pharmacol. 600 (2008), 78–82.
37. Pham-Marcou, T.A., Beloeil, H., Sun, X., Gentili, M., Yaici, D., Benoit, G., Benhamou, D., Mazoit, J.X., Antinociceptive effect of resveratrol in carrageenan-evoked hyperalgesia in rats: prolonged effect related to COX-2 expression impairment. Pain 140 (2008), 274–283.
38. Elmali, N., Baysal, O., Harma, A., Esenkaya, I., Mizrak, B., Effects of resveratrol in inflammatory arthritis. Inflammation 30 (2007), 1–6.
39. Ma, Z.H., Ma, Q.Y., Wang, L.C., Sha, H.C., Wu, S.L., Zhang, M., Effect of resveratrol on peritoneal macrophages in rats with severe acute pancreatitis. Inflamm. Res. 54 (2005), 522–527.
40. Chiou, Y.S., Tsai, M.L., Nagabhushanam, K., Wang, Y.J., Wu, C.H., Ho, C.T., Pan, M.H., Pterostilbene is more potent than resveratrol in preventing azoxymethane (AOM)-induced colon tumorigenesis via activation of the NF-E2-related factor 2 (Nrf2)-mediated antioxidant signaling pathway. J. Agric. Food Chem. 59 (2011), 2725–2733.
41. Cichocki, M., Paluszczak, J., Szaefer, H., Piechowiak, A., Rimando, A.M., Baer-Dubowska, W., Pterostilbene is equally potent as resveratrol in inhibiting 12-O-tetradecanoylphorbol-13-acetate activated NFκB, AP-1, COX-2, and iNOS in mouse epidermis. Mol. Nutr. Food Res. 52 (2008), S62–S70.
42. Martín, A.R., Villegas, I., Sánchez-Hidalgo, M., de la Lastra, C.A., The effects of resveratrol a phytoalexin derived from red wines, on chronic inflammation induced in an experimentally induced colitis model. Br. J. Pharmacol. 147 (2006), 873–885.
43. Bishayee, A., Waghray, A., Barnes, K.F., Mbimba, T., Bhatia, D., Chatterjee, M., Darvesh, A.S., Suppression of the inflammatory cascade is implicated in resveratrol chemoprevention of experimental hepatocarcinogenesis. Pharm. Res. 27 (2010), 1080–1091.
44. Choo, Q.Y., Yeo, S.C.M., Ho, P.C., Tanaka, Y., Lin, H.S., Pterostilbene surpassed resveratrol for anti-inflammatory application: potency consideration and pharmacokinetics perspective. J. Funct. Food. 11 (2014), 352–362.
45. Kang, O.H., Jang, H.J., Chae, H.S., Oh, Y.C., Choi, J.G., Lee, Y.S., Kim, J.H., Kim, Y.C., Sohn, D.H., Park, H., Kwon, D.Y., Anti-inflammatory mechanisms of resveratrol in activated HMC-1 cells: pivotal roles of NF-κB and MAPK. Pharmacol. Res. 59 (2009), 330–337.
46. Bi, X.L., Yang, J.Y., Dong, Y.X., Wang, J.M., Cui, Y.H., Ikeshima, T., Zhao, Y.Q., Wu, C.F., Resveratrol inhibits nitric oxide and TNF-α production by lipopolysaccharide-activated microglia. Int. Immunopharmacol. 5 (2005), 185–193.
47. Oh, Y.C., Kang, O.H., Choi, J.G., Chae, H.S., Lee, Y.S., Brice, O.O., Jung, H.J., Hong, S.H., Lee, Y.M., Kwon, D.Y., Anti-inflammatory effect of resveratrol by inhibition of IL-8 production in LPS-induced THP-1 cells. Am. J. Chin. Med. 37 (2009), 1203–1214.
48. Gonzales, A.M., Orlando, R.A., Curcumin and resveratrol inhibit nuclear factor-kappaB-mediated cytokine expression in adipocytes. Nutr. Metab., 5, 2008, 17.
49. Busch, F., Mobasheri, A., Shayan, P., Stahlmann, R., Shakibaei, M., Sirt-1 is required for the inhibition of apoptosis and inflammatory responses in human tenocytes. J. Biol. Chem. 287 (2012), 25770–25781.
50. Calabriso, N., Scoditti, E., Massaro, M., Pellegrino, M., Storelli, C., Ingrosso, I., Giovinazzo, G., Carluccio, M.A., Multiple anti-inflammatory and anti-atherosclerotic properties of red wine polyphenolic extracts: differential role of hydroxycinnamic acids, flavonols and stilbenes on endothelial inflammatory gene expression. Eur. J. Nutr. 55 (2016), 477–489.
51. Csiszar, A., Labinskyy, N., Podlutsky, A., Kaminski, P.M., Wolin, M.S., Zhang, C., Mukhopadhyay, P., Pacher, P., Hu, F., de Cabo, R., Ballabh, P., Ungvari, Z., Vasoprotective effects of resveratrol and SIRT1: attenuation of cigarette smoke-induced oxidative stress and proinflammatory phenotypic alterations. Am. J. Physiol. Heart Circ. Physiol. 294 (2008), H2721–H2735.
52. Csiszar, A., Sosnowska, D., Wang, M., Lakatta, E.G., Sonntag, W.E., Ungvari, Z., Age-associated proinflammatory secretory phenotype in vascular smooth muscle cells from the non-human primate Macaca mulatta: reversal by resveratrol treatment. J. Gerontol. A Biol. Sci. Med. Sci. 67 (2012), 811–820.
53. Shen, M.Y., Hsiao, G., Liu, C.L., Fong, T.H., Lin, K.H., Chou, D.S., Sheu, J.R., Inhibitory mechanisms of resveratrol in platelet activation: pivotal roles of p38 MAPK and NO/cyclic GMP. Br. J. Haematol. 139 (2007), 475–485.
54. Do, G.M., Jung, U.J., Park, H.J., Kwon, E.Y., Jeon, S.M., McGregor, R.A., Choi, M.S., Resveratrol ameliorates diabetes-related metabolic changes via activation of AMP-activated protein kinase and its downstream targets in db/db mice. Mol. Nutr. Food Res. 56 (2012), 1282–1291.
55. Kundu, J.K., Shin, Y.K., Surh, Y.J., Resveratrol modulates phorbol ester-induced pro-inflammatory signal transduction pathways in mouse skin in vivo: NF-kB and AP-1 as prime targets. Biochem. Pharmacol. 72 (2006), 1506–1515.
56. Chung, E.Y., Kim, B.H., Hong, J.T., Lee, C.K., Ahn, B., Nam, S.Y., Han, S.B., Kim, Y., Resveratrol down-regulates interferon-γ-inducible inflammatory genes in macrophages: molecular mechanism via decreased STAT-1 activation. J. Nutr. Biochem. 22 (2011), 902–909.
57. Djoko, B., Chiou, R.Y., Shee, J.J., Liu, Y.W., Characterization of immunological activities of peanut stilbenoids arachidin-1, piceatannol, and resveratrol on lipopolysaccharide-induced inflammation of RAW 264.7 macrophages. J. Agric. Food Chem. 55 (2007), 2376–2383.
58. Carey, A.N., Fisher, D.R., Rimando, A.M., Gomes, S.M., Bielinski, D.F., Shukitt-Hale, B., Stilbenes and anthocyanins reduce stress signaling in BV-2 mouse microglia. J. Agric. Food Chem. 61 (2013), 5979–5986.
59. Arunachalam, G., Yao, H., Sundar, I.K., Caito, S., Rahman, I., SIRT1 regulates oxidant- and cigarette smoke-induced eNOS acetylation in endothelial cells: role of resveratrol. Biochem. Biophys. Res. Commun. 393 (2010), 66–72.
60. Son, Y., Chung, H.T., Pae, H.O., Differential effects of resveratrol and its natural analogs piceatannol and 3,5,4’-trans-trimethoxystilbene, on anti-inflammatory heme oxigenase-1 expression in RAW264.7 macrophages. Biofactors 40 (2014), 138–145.
61. Pitozzi, V., Mocali, A., Laurenzana, A., Giannoni, E., Cifola, I., Battaglia, C., Chiarugi, P., Dolara, P., Giovannelli, L., Chronic resveratrol treatment ameliorates cell adhesion and mitigates the inflammatory phenotype in senescent human fibroblasts. J. Gerontol. A. Biol. Sci. Med. Sci. 68 (2013), 371–381.
62. Bureau, G., Longpré, F., Martinoli, M.G., Resveratrol and quercetin two natural polyphenols, reduce apoptotic neuronal cell death induced by neuroinflammation. J. Neurosci. Res. 86 (2008), 403–410.
63. Salado, C., Olaso, E., Gallot, N., Valcarcel, M., Egilegor, E., Mendoza, L., Vidal-Vanaclocha, F., Resveratrol prevents inflammation-dependent hepatic melanoma metastasis by inhibiting the secretion and effects of interleukin-18. J. Transl. Med., 9, 2011, 59.
64. Shin, J.A., Lee, H., Lim, Y.K., Koh, Y., Choi, J.H., Park, E.M., Therapeutic effects of resveratrol during acute periods following experimental ischemic stroke. J. Neuroimmunol. 227 (2010), 93–100.
65. Liu, C., Shi, Z., Fan, L., Zhang, C., Wang, K., Wang, B., Resveratrol improves neuron protection and functional recovery in rat model of spinal cord injury. Brain Res. 1374 (2011), 100–109.
66. Mbimba, T., Awale, P., Bhatia, D., Geldenhuys, W.J., Darvesh, A.S., Carroll, R.T., Bishayee, A., Alteration of hepatic proinflammatory cytokines is involved in the resveratrol-mediated chemoprevention of chemically-induced hepatocarcinogenesis. Curr. Pharm. Biotechnol. 13 (2012), 229–234.
67. Csiszar, A., Labinskyy, N., Olson, S., Pinto, J.T., Gupte, S., Wu, J.M., Hu, F., Ballabh, P., Podlutsky, A., Losonczy, G., de Cabo, R., Mathew, R., Wolin, M.S., Ungvari, Z., Resveratrol prevents monocrotaline-induced pulmonary hypertension in rats. Hypertension 54 (2009), 668–675.
68. Sehirli, O., Tozan, A., Omurtag, G.Z., Cetinel, S., Contuk, G., Gedik, N., Sener, G., Protective effect of resveratrol against naphthalene-induced oxidative stress in mice. Ecotoxicol. Environ. Saf. 71 (2008), 301–308.
69. Wood, L.G., Wark, P.A.B., Garg, M.L., Antioxidant and anti-Inflammatory effects of resveratrol in airway disease. Antioxid. Redox Sign. 13 (2010), 1535–1548.
70. Abbas, A.M., Cardioprotective effect of resveratrol analogue isorhapontigenin versus omega-3 fatty acids in isoproterenol-induced myocardial infarction in rats. J. Physiol. Biochem. 72 (2016), 469–484.
71. Min+ mouse and cyclooxygenase-2 in human-derived colon cancer cells. Int. J. Cancer 115 (2005), 194–201.
72. Rayalam, S., Yang, J.Y., Ambati, S., Della-Fera, M.A., Baile, C.A., Resveratrol induces apoptosis and inhibits adipogenesis in 3T3-L1 adipocytes. Phytother. Res. 22 (2008), 1367–1371.
73. Kopec, A., Piatkowska, E., Leszczynska, T., Koronowicz, An., Effect of long term administration of resveratrol on lipid concentration in selected organs and liver's histology in rats fed high fructose diet. J. Funct. Food. 5 (2013), 299–305.
74. Yang, Y.M., Chen, J.Z., Wang, X.X., Wang, S.J., Hu, H.-, Wang, H.Q., Resveratrol attenuates thromboxane A2 receptor agonist induced platelet activation by reducing phospholipase C activity. Eur. J. Pharmacol. 583 (2008), 148–155.
75. Potter, G.A., Patterson, L.H., Wanogho, E., Perry, P.J., Butler, P.C., Ijaz, T., Ruparelia, K.C., Lamb, J.H., Farmer, P.B., Stanley, L.A., Burke, M.D., The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1. Br. J. Cancer. 86 (2002), 774–778.
76. Liu, D., Kim, D.H., Park, J.M., Na, H.K., Surh, Y.J., Piceatannol inhibits phorbol ester-induced NF-κB activation and COX-2 expression in cultured human mammary epithelial cells. Nutr. Cancer 61 (2009), 855–863.
77. Jayasooriya, R.G., Lee, Y.G., Kang, C.H., Lee, K.T., Choi, Y.H., Park, S.Y., Hwang, J.K., Kim, G.Y., Piceatannol inhibits MMP-9-dependent invasion of tumor necrosis factor-α-stimulated DU145 cells by suppressing the Akt-mediated nuclear factor-κB pathway. Oncol. Lett. 5 (2013), 341–347.
78. Son, P.S., Park, S.A., Na, H.K., Jue, D.M., Kim, S., Surh, Y.J., Piceatannol, a catechol-type polyphenol, inhibits phorbol ester-induced NF-kB activation and cyclooxygenase-2 expression in human breast epithelial cells: cysteine 179 of IKKb as a potential target. Carcinogenesis 31 (2010), 1442–1449.
79. Jin, C.Y., Moon, D.O., Lee, K.J., Kim, M.O., Lee, J.D., Choi, Y.H., Park, Y.M., Kim, G.Y., Piceatannol attenuates lipopolysaccharide-induced NF-κB activation and NF-κB-related proinflammatory mediators in BV2 microglia. Pharmacol. Res. 54 (2006), 461–467.
80. Ashikawa, K., Majumdar, S., Banerjee, S., Bharti, A.C., Shishodia, S., Aggarwal, B.B., Piceatannol inhibits TNF-induced NF-κB activation and NF-κB-mediated gene expression through suppression of IκBα kinase and p65 phosphorylation. J. Immunol. 169 (2002), 6490–6497.
81. Szekeres, T., Saiko, P., Fritzer-Szekeres, M., Djavan, B., Jäger, W., Chemopreventive effects of resveratrol and resveratrol derivatives. Ann. N. Y. Acad. Sci. 1215 (2011), 89–95.
82. Murias, M., Jager, W., Handler, N., Erker, T., Horvath, Z., Szekeres, T., Nohl, H., Gille, L., Antioxidant: prooxidant and cytotoxic activity of hydroxylated resveratrol analogues: structure-activity relationship. Biochem. Pharmacol. 69 (2005), 903–912.
83. Liu, L., Li, J., Kundu, J.K., Surh, Y.J., Piceatannol inhibits phorbol ester-induced expression of COX-2 and iNOS in HR-1 hairless mouse skin by blocking the activation of NF-κB and AP-1. Inflamm. Res. 63 (2014), 1013–1021.
84. Islam, S., Hassan, F., Mu, M.M., Ito, H., Koide, N., Mori, I., Yoshida, T., Yokochi, T., Piceatannol prevents lipopolysaccharide (LPS)-induced nitric oxide (NO) production and nuclear factor (NF)-κB activation by inhibiting I(B kinase (IKK). Microbiol. Immunol. 48 (2004), 729–736.
85. 106-126-induced iNOS activation mediated by CD36 in BV2 microglia. Acta Biochim. Biophys. Sin. 45 (2013), 763–772.
86. Hijona, E., Aguirre, L., Pérez-Matute, P., Villanueva-Millán, M.J., Mosqueda-Solis, A., Hasnaoui, M., Nepveu, F., Senard, J.M., Bujanda, L., Aldámiz-Echevarría, L., Llarena, M., Andrade, F., Perio, P., Leboulanger, F., Hijona, L., Arbones-Mainar, J.M., Portillo, M.P., Carpéné, C., Limited beneficial effects of piceatannol supplementation on obesity complications in the obese Zucker rat: gut microbiota, metabolic, endocrine, and cardiac aspects. J. Physiol. Biochem. 72 (2016), 567–582.
87. Llarena, M., Andrade, F., Hasnaoui, M., Portillo, M.P., Pérez-Matute, P., Arbones-Mainar, J.M., Hijona, E., Villanueva-Millán, M.J., Aguirre, L., Carpéné, C., Aldámiz-Echevarría, L., Potential renoprotective effects of piceatannol in ameliorating the early-stage nephropathy associated with obesity in obese Zucker rats. J. Physiol. Biochem. 72 (2016), 555–566.
88. Uchida-Maruki, H., Inagaki, H., Ito, R., Kurita, I., Sai, M., Ito, T., Piceatannol lowers the blood glucose level in diabetic mice. Biol. Pharm. Bull. 38 (2015), 629–633.
89. Youn, J., Lee, J.S., Na, H.K., Kundu, J.K., Surh, Y.J., Resveratrol and piceatannol inhibit iNOS expression and NF-κB activation in dextran sulfate sodium-induced mouse colitis. Nutr. Cancer 61 (2009), 847–854.
90. Yum, S., Jeong, S., Lee, S., Nam, J., Kim, W., Yoo, J.W., Kim, M.S., Lee, B.L., Jung, Y., Colon-targeted delivery of piceatannol enhances anti-colitic effects of the natural product: potential molecular mechanisms for therapeutic enhancement. Drug. Des. Devel. Ther. 9 (2015), 4247–4258.
91. Yang, L., Rui, Y., Du, L., Yu, Y., Liu, L., Protective role of piceatannol in amikacin-induced renal damage in neonatal rats. Biomed. Res. India 28 (2017), 1142–1147.
92. Zhou, Y., Zheng, J., Li, Y., Xu, D.P., Li, S., Chen, Y.M., Li, H.B., Natural polyphenols for prevention and treatment of cancer. Nutrients, 8, 2016, E515.
93. Yeo, S.C., Ho, P.C., Lin, H.S., Pharmacokinetics of pterostilbene in Sprague-Dawley rats: the impacts of aqueous solubility fasting, dose escalation, and dosing route on bioavailability. Mol. Nutr. Food. Res. 57 (2013), 1015–1025.
94. Pan, M.H., Chang, Y.H., Tsai, M.L., Lai, C.S., Ho, S.Y., Badmaev, V., Ho, C.T., Pterostilbene suppressed lipopolysaccharide-induced up-expression of iNOS and COX-2 in murine macrophages. J. Agric. Food. Chem. 56 (2008), 7502–7509.
95. Hou, Y., Xie, G., Miao, F., Ding, L., Mou, Y., Wang, L., Su, G., Chen, G., Yang, J., Wu, C., Pterostilbene attenuates lipopolysaccharide-induced learning and memory impairment possibly via inhibiting microglia activation and protecting neuronal injury in mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 54 (2014), 92–102.
96. Paul, S., Rimando, A.M., Lee, H.J., Ji, Y., Reddy, B.S., Suh, N., Anti-inflammatory action of pterostilbene is mediated through the p38 mitogen-activated protein kinase pathway in colon cancer cells. Cancer Prev. Res. 2 (2009), 650–657.
97. Liu, J., Fan, C., Yu, L., Yang, Y., Jiang, S., Ma, Z., Hu, W., Li, T., Yang, Z., Tian, T., Duan, W., Yu, S., Pterostilbene exerts an anti-inflammatory effect via regulating endoplasmic reticulum stress in endothelial cells. Cytokine 77 (2016), 88–97.
98. Zhang, L., Zhou, G., Song, W., Tan, X., Guo, Y., Zhou, B., Jing, H., Zhao, S., Chen, L., Pterostilbene protects vascular endothelial cells against oxidized low-density lipoprotein-induced apoptosis in vitro and in vivo. Apoptosis 17 (2012), 25–36.
99. Kutil, Z., Pribylova, M., Temml, V., Schuster, D., Marsik, P., Susimamani, E., Lou, J.D., Vanek, T., Landa, P., Effect of dietary stilbenes on 5-lipoxygenase and cyclooxygenase activities in vitro. Int. J. Food Prop. 18 (2015), 1471–1477.
100. Perecko, T., Drabikova, K., Lojek, A., Ciz, M., Ponist, S., Bauerova, K., Nosal, R., Harmatha, J., Jancinova, V., The effects of pterostilbene on neutrophil activity in experimental model of arthritis. Biomed. Res. Int., 2013, 2013, 106041.
101. Chang, J., Rimando, A., Pallas, M., Camins, A., Porquet, D., Reeves, J., Shukitt-Hale, B., Smith, M.A., Joseph, J.A., Casadesus, G., Low-dose pterostilbene but not resveratrol, is a potent neuromodulator in aging and Alzheimer's disease. Neurobiol. Aging. 33 (2012), 2062–2071.
102. Rimando, A.M., Nagmani, R., Feller, D.R., Yokoyama, W., Pterostilbene, a new agonist for the peroxisome proliferator-activated receptor α-isoform, lowers plasma lipoproteins and cholesterol in hypercholesterolemic hamsters. J. Agric. Food. Chem. 53 (2005), 3403–3407.
103. El-Sayed, el-S.M., Mansour, A.M., Nady, M.E., Protective effects of pterostilbene against acetaminophen-induced hepatotoxicity in rats. J. Biochem. Mol. Toxicol. 29 (2015), 35–42.
104. Riche, D.M., Riche, K.D., Blackshear, C.T., McEwen, C.L., Sherman, J.J., Wofford, M.R., Griswold, M.E., Pterostilbene on metabolic parameters: a randomized, double-blind, and placebo-controlled trial. Evid. Based. Complement. Alternat. Med., 2014, 2014, 459165.
105. Deng, Y.H., Alex, D., Huang, H.Q., Wang, N., Yu, N., Wang, Y.T., Leung, G.P., Lee, S.M., Inhibition of TNF-α-mediated endothelial cell-monocyte cell adhesion and adhesion molecules expression by the resveratrol derivative, trans-3,5,4’-trimethoxystilbene. Phytother. Res. 25 (2011), 451–457.
106. Liu, B., Luo, X.J., Yang, Z.B., Zhang, J.J., Li, T.B., Zhang, X.J., Ma, Q.L., Zhang, G.G., Hu, C.P., Peng, J., Inhibition of NOX/VPO1 pathway and inflammatory reaction by trimethoxystilbene in prevention of cardiovascular remodeling in hypoxia-induced pulmonary hypertensive rats. J. Cardiovasc. Pharmacol. 63 (2014), 567–576.
107. Maneechai, S., Likhitwitayawuid, K., Sritularak, B., Palanuvej, C., Ruangrungsi, N., Sirisa-Ard, P., Quantitative analysis of oxyresveratrol content in Artocarpus lakoocha and ‘Puag-Haad’. Med. Princ. Pract. 18 (2009), 223–227.
108. Jo, S.P., Kim, J.K., Lim, Y.H., Antihyperlipidemic effects of rhapontin and rhapontigenin from rheum undulatum in rats fed a high-cholesterol diet. Planta Med. 80 (2014), 1067–1071.
109. Remsberg, C.M., Martinez, S.E., Akinwumi, B.C., Anderson, H.D., Takemoto, J.K., Sayre, C.L., Davies, N.M., Preclinical pharmacokinetics and pharmacodynamics and content analysis of gnetol in foodstuffs. Phytother. Res. 29 (2015), 1168–1179.
110. Ohguchi, K., Tanaka, T., Iliya, I., Ito, T., Iinuma, M., Matsumoto, K., Akao, Y., Nozawa, Y., Gnetol as a potent tyrosinase inhibitor from genus Gnetum. Biosci. Biotechnol. Biochem. 67 (2003), 663–665.
111. Sermboonpaisarn, T., Sawasdee, P., Potent and selective butyrylcholinesterase inhibitors from Ficus foveolata. Fitoterapia 83 (2012), 780–784.
112. Huang, M.Y., Lin, J., Lu, K., Xu, H.G., Geng, Z.Z., Sun, P.H., Chen, W.M., Anti-Inflammatory effects of cajaninstilbene acid and its derivatives. J. Agric. Food. Chem. 64 (2016), 2893–2900.
113. Liang, L., Luo, M., Fu, Y., Zu, Y., Wang, W., Gu, C., Zhao, C., Li, C., Efferth, T., Cajaninstilbene acid (CSA) exerts cytoprotective effects against oxidative stress through the Nrf2-dependent antioxidant pathway. Toxicol. Lett. 219 (2013), 254–261.
114. Patel, N.K., Bhutani, K.K., Pinostrobin and Cajanus lactone isolated from Cajanus cajan (L.) leaves inhibits TNF-α and IL-1β production: in vitro and in vivo experimentation. Phytomedicine 21 (2014), 946–953.
115. Sun, Y., Wu, X., Cai, X., Song, M., Zheng, J., Pan, C., Qiu, P., Zhang, L., Zhou, S., Tang, Z., Xiao, H., Identification of pinostilbene as a major colonic metabolite of pterostilbene and its inhibitory effects on colon cancer cells. Mol. Nutr. Food. Res. 60 (2016), 1924–1932.
116. Jancinova, V., Nosal, R., Lojek, A., Ciz, M., Ambrozova, G., Mihalova, D., Bauerova, K., Harmatha, J., Perecko, T., Formation of reactive oxygen and nitrogen species in the presence of pinosylvin − an analogue of resveratrol. Neuro Endocrinol. Lett. 31 (2010), 79–83.
117. Jančinová, V., Perečko, T., Nosáľ, R., Harmatha, J., Smidrkal, J., Drábiková, K., The natural stilbenoid pinosylvin and activated neutrophils: effects on oxidative burst protein kinase C, apoptosis and efficiency in adjuvant arthritis. Acta Pharmacol. Sin. 33 (2012), 1285–1292.
118. Cai, T., Cai, Y., cis-Ampelopsin E a stilbene isolated from the seeds of Paeonia suffruticosa, inhibits lipopolysaccharide-stimulated nitric oxide production in RAW 2647 macrophages via blockade of nuclear factor-kappa B signaling pathway. Biol. Pharm. Bull. 34 (2011), 1501–1507.
119. Esatbeyoglu, T., Ewald, P., Yasui, Y., Yokokawa, H., Wagner, A.E., Matsugo, S., Winterhalter, P., Rimbach, G., Characterization, Chemical, Free radical scavenging, and cellular antioxidant and anti-inflammatory properties of a stilbenoid-rich root extract of Vitis vinifera. Oxid. Med. Cell. Longev., 2016, 2016, 8591286.
120. Calabriso, N., Massaro, M., Scoditti, E., Pellegrino, M., Ingrosso, I., Giovinazzo, G., Carluccio, M.A., Red grape skin polyphenols blunt matrix metalloproteinase-2 and −9 activity and expression in cell models of vascular inflammation: protective role in degenerative and inflammatory diseases. Molecules, 21, 2016, E1147.
121. Regulski, M., Regulska, K., Prukała, W., Piotrowska, H., Stanisz, B., Murias, M., COX-2 inhibitors: a novel strategy in the management of breast cancer. Drug. Discov. Today 21 (2016), 598–615.
122. Tomé-Carneiro, J., Larrosa, M., González-Sarrías, A., Tomás-Barberán, F.A., García-Conesa, M.T., Espín, J.C., Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence. Curr. Pharm. Des. 19 (2013), 6064–6093.
123. Wenzel, E., Somoza, V., Metabolism and bioavailability of transresveratrol. Mol. Nutr. Food Res. 49 (2005), 472–481.
124. Rotches-Ribalta, M., Andres-Lacueva, C., Estruch, R., Escribano, E., Urpi-Sarda, M., Pharmacokinetics of resveratrol metabolic profile in healthy humans after moderate consumption of red wine and grape extract tablets. Pharmacol. Res. Off. J. Ital. Pharmacol. Soc. 66 (2012), 375–382.
125. Karki, S.S., Bhutle, S.R., Pedgaonkar, G.S., Zubaidha, P.K., Shaikh, R.M., Rajput, C.G., Shendarkar, G.S., Synthesis and biological evaluation of some stilbene-based analogues. Med. Chem. Res., 20, 2011, 1158.
126. Almeida, L., Vaz-da-Silva, M., Falcão, A., Soares, E., Costa, R., Loureiro, A.I., Fernandes-Lopes, C., Rocha, J.F., Nunes, T., Wright, L., Soares-da-Silva, P., Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol. Nutr. Food. Res. 53 (2009), S7–S15.
127. Walle, T., Bioavailability of resveratrol. Ann. N. Y. Acad. Sci. 1215 (2011), 9–15.
128. Bode, L.M., Bunzel, D., Huch, M., Cho, G.S., Ruhland, D., Bunzel, M., Bub, A., Franz, C.M., Kulling, S.E., In vivo and in vitro metabolism of trans-resveratrol by human gut microbiota. Am. J. Clin. Nutr. 97 (2013), 295–309.
129. Roupe, K.A., Yáñez, J.A., Teng, X.W., Davies, N.M., Pharmacokinetics of selected stilbenes: rhapontigenin: piceatannol and pinosylvin in rats. J. Pharm. Pharmacol. 58 (2006), 1443–1450.
130. Miksits, M., Maier-Salamon, A., Vo, T.P., Sulyok, M., Schuhmacher, R., Szekeres, T., Jäger, W., Glucuronidation of piceatannol by human liver microsomes: major role of UGT1A1: UGT1A8 and UGT1A10. J. Pharm. Pharmacol. 62 (2010), 47–54.
131. Roupe, K., Teng, X.W., Fu, X., Meadows, G.G., Davies, N.M., Determination of piceatannol in rat serum and liver microsomes: pharmacokinetics and phase I and II biotransformation. Biomed. Chromatogr. 18 (2004), 486–491.
132. Lin, H.S., Yue, B.D., Ho, P.C., Determination of pterostilbene in rat plasma by a simple HPLC-UV method and its application in pre-clinical pharmacokinetic study. Biomed. Chromatogr. 23 (2009), 1308–1315.
133. Yeo, S.C., Ho, P.C., Lin, H.S., Pharmacokinetics of pterostilbene in Sprague-Dawley rats: the impacts of aqueous solubility fasting, dose escalation, and dosing route on bioavailability. Mol. Nutr. Food. Res. 57 (2013), 1015–1025.
134. Rodríguez-Bonilla, P., López-Nicolás, J.M., García-Carmona, F., Use of reversed phase high pressure liquid chromatography for the physicochemical and thermodynamic characterization of oxyresveratrol/β-cyclodextrin complexes. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 878 (2010), 1569–1575.
135. Hua, X., Fu, Y.J., Zu, Y.G., Wu, N., Kong, Y., Li, J., Peng, X., Efferth, T., Plasma pharmacokinetics and tissue distribution study of cajaninstilbene acid in rats by liquid chromatography with tandem mass spectrometry. J. Pharm. Biomed. Anal. 52 (2010), 273–279.
136. Lin, H.S., Ho, P.C., A rapid HPLC method for the quantification of 3,5,4’-trimethoxy-trans-stilbene (TMS) in rat plasma and its application in pharmacokinetic study. J. Pharm. Biomed. Anal. 49 (2009), 387–392.
137. Walle, T., Hsieh, F., DeLegge, M.H., Oatis, J.E. Jr., Walle, U.K., High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos. 32 (2004), 1377–1382.
138. Boocock, D.J., Faust, G.E., Patel, K.R., Schinas, A.M., Brown, V.A., Ducharme, M.P., Booth, T.D., Crowell, J.A., Perloff, M., Gescher, A.J., Steward, W.P., Brenner, D.E., Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol. Biomarkers. Prev. 16 (2007), 1246–1252.
139. Juan, M.E., Maijó, M., Planas, J.M., Quantification of trans-resveratrol and its metabolites in rat plasma and tissues by HPLC. J. Pharm. Biomed. Anal. 51 (2010), 391–398.
140. Lu, D.L., Ding, D.J., Yan, W.J., Li, R.R., Dai, F., Wang, Q., Yu, S.S., Li, Y., Jin, X.L., Zhou, B., Influence of glucuronidation and reduction modifications of resveratrol on its biological activities. Chembiochem 14 (2013), 1094–1104.
141. Calamini, B., Ratia, K., Malkowski, M.G., Cuendet, M., Pezzuto, J.M., Santarsiero, B.D., Mesecar, A.D., Pleiotropic mechanisms facilitated by resveratrol and its metabolites. Biochem. J. 429 (2010), 273–282.
142. Patel, K.R., Andreadi, C., Britton, R.G., Horner-Glister, E., Karmokar, A., Sale, S., Brown, V.A., Brenner, D.E., Singh, R., Steward, W.P., Gescher, A.J., Brown, K., Sulfate metabolites provide an intracellular pool for resveratrol generation and induce autophagy with senescence. Sci. Transl. Med., 5, 2013, 205ra133.
143. Poulsen, M.M., Fjeldborg, K., Ornstrup, M.J., Kjær, T.N., Nøhr, M.K., Pedersen, S.B., Resveratrol and inflammation. Challenges in translating pre-clinical findings to improved patient outcomes. Biochim. Biophys. Acta 1852 (2015), 1124–1136.
144. Fabbrocini, G., Staibano, S., De Rosa, G., Battimiello, V., Fardella, N., Ilardi, G., La Rotonda, M.I., Longobardi, A., Mazzella, M., Siano, M., Pastore, F., De Vita, V., Vecchione, M.L., Ayala, F., Resveratrol-containing gel for the treatment of acne vulgaris: a single-blind vehicle-controlled, pilot study. Am. J. Clin. Dermatol. 12 (2011), 133–141.
145. Buonocore, D., Lazzeretti, A., Tocabens, P., Nobile, V., Cestone, E., Santin, G., Bottone, M.G., Marzatico, F., Resveratrol-procyanidin blend: nutraceutical and antiaging efficacy evaluated in a placebocontrolled, double-blind study. Clin. Cosmet. Investig. Dermatol. 5 (2012), 159–165.
146. Tomé-Carneiro, J., Gonzálvez, M., Larrosa, M., García-Almagro, F.J., Avilés-Plaza, F., Parra, S., Yáñez-Gascón, M.J., Ruiz-Ros, J.A., García-Conesa, M.T., Tomás-Barberán, F.A., Espín, J.C., Consumption of a grape extract supplement containing resveratrol decreases oxidized LDL and ApoB in patients undergoing primary prevention of cardiovascular disease: a triple-blind, 6-month follow-up, placebo-controlled, randomized trial. Mol. Nutr. Food Res. 56 (2012), 810–821.
147. Tomé-Carneiro, J., Gonzálvez, M., Larrosa, M., Yáñez-Gascón, M.J., García-Almagro, F.J., Ruiz-Ros, J.A., García-Conesa, M.T., Tomás-Barberán, F.A., Espín, J.C., One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease. Am. J. Cardiol. 110 (2012), 356–363.
148. Magyar, K., Halmosi, R., Palfi, A., Feher, G., Czopf, L., Fulop, A., Battyany, I., Sumegi, B., Toth, K., Szabados, E., Cardioprotection by resveratrol: a human clinical trial in patients with stable coronary artery disease. Clin. Hemorheol. Microcirc. 50 (2012), 179–187.
149. Tomé-Carneiro, J., Gonzálvez, M., Larrosa, M., Yáñez-Gascón, M.J., García-Almagro, F.J., Ruiz-Ros, J.A., Tomás-Barberán, F.A., García-Conesa, M.T., Espín, J.C., Grape resveratrol increases serum adiponectin and downregulates inflammatory genes in peripheral blood mononuclear cells: a triple-blind, placebo-controlled, one-year clinical trial in patients with stable coronary artery disease. Cardiovasc. Drugs Ther. 27 (2013), 37–48.
150. Maia, H. Jr., Haddad, C., Pinheiro, N., Casoy, J., Advantages of the association of resveratrol with oral contraceptives for management of endometriosis-related pain. Int. J. Womens Health 4 (2012), 543–549.
151. Shi, G., Hua, M., Xu, Q., Ren, T., Resveratrol improves treatment outcome and laboratory parameters in patients with Takayasu arteritis: a randomized double-blind and placebo-controlled trial. Immunobiology 222 (2017), 164–168.
152. Samsami-Kor, M., Daryani, N.E., Asl, P.R., Hekmatdoost, A., Anti-Inflammatory effects of resveratrol in patients with ulcerative colitis: a randomized double-Blind, placebo-controlled pilot study. Arch. Med. Res. 46 (2015), 280–285.
153. Ghanim, H., Sia, C.L., Korzeniewski, K., Lohano, T., Abuaysheh, S., Marumganti, A., Chaudhuri, A., Dandona, P., A resveratrol and polyphenol preparation suppresses oxidative and inflammatory stress response to a high-fat, high-carbohydrate meal. J. Clin. Endocrinol. Metab. 96 (2011), 1409–1414.
154. Patel, K.R., Brown, V.A., Jones, D.J., Britton, R.G., Hemingway, D., Miller, A.S., West, K.P., Booth, T.D., Perloff, M., Crowell, J.A., Brenner, D.E., Steward, W.P., Gescher, A.J., Brown, K., Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res. 70 (2010), 7392–7399.
155. Howells, L.M., Berry, D.P., Elliott, P.J., Jacobson, E.W., Hoffmann, E., Hegarty, B., Brown, K., Steward, W.P., Gescher, A.J., Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases-safety, pharmacokinetics, and pharmacodynamics. Cancer Prev. Res. (Phila) 4 (2011), 1419–1425.
156. Heger, A., Ferk, F., Nersesyan, A., Szekeres, T., Kundi, M., Wagner, K.H., Haidinger, G., Mišík, M., Knasmüller, S., Intake of a resveratrol-containing dietary supplement has no impact on DNA stability in healthy subjects. Mutat. Res. 749 (2012), 82–86.
157. Yoshino, J., Conte, C., Fontana, L., Mittendorfer, B., Imai, S., Schechtman, K.B., Gu, C., Kunz, I., Rossi Fanelli, F., Patterson, B.W., Klein, S., Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. Cell Metab. 16 (2012), 658–664.
158. Poulsen, M.M., Vestergaard, P.F., Clasen, B.F., Radko, Y., Christensen, L.P., Stødkilde-Jørgensen, H., Møller, N., Jessen, N., Pedersen, S.B., Jørgensen, J.O., High-dose resveratrol supplementation in obese men: an investigator-initiated randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes 62 (2013), 1186–1195.
159. Saldanha, J.F., Leal, V.O., Rizzetto, F., Grimmer, G.H., Ribeiro-Alves, M., Daleprane, J.B., Carraro-Eduardo, J.C., Mafra, D., Effects of resveratrol supplementation in nrf2 and NF-κB expressions in nondialyzed chronic kidney disease patients: a randomized, double-blind, placebo-controlled, crossover clinical trial. J. Ren. Nutr. 26 (2016), 401–406.
160. Bo, S., Ponzo, V., Ciccone, G., Evangelista, A., Saba, F., Goitre, I., Procopio, M., Pagano, G.F., Cassader, M., Gambino, R., Six months of resveratrol supplementation has no measurable effect in type 2 diabetic patients. A randomized, double blind, placebo-controlled trial. Pharmacol. Res. 111 (2016), 896–905.
161. van der Made, S.M., Plat, J., Mensink, R.P., Resveratrol does not influence metabolic risk markers related to cardiovascular health in overweight and slightly obese subjects: a randomized, placebo-controlled crossover trial. PLoS One, 10, 2015, e0118393.
162. Ruiz, M.J., Fernández, M., Picó, Y., Mañes, J., Asensi, M., Carda, C., Asensio, G., Estrela, J.M., Dietary administration of high doses of pterostilbene and quercetin to mice is not toxic. J. Agric. Food. Chem. 57 (2009), 3180–3186.
163. Brown, V.A., Patel, K.R., Viskaduraki, M., Crowell, J.A., Perloff, M., Booth, T.D., Vasilinin, G., Sen, A., Schinas, A.M., Piccirilli, G., Brown, K., Steward, W.P., Gescher, A.J., Brenner, D.E., Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res. 70 (2010), 9003–9011.
164. Cosco, D., Paolino, D., Maiuolo, J., Marzio, L.D., Carafa, M., Ventura, C.A., Fresta, M., Ultradeformable liposomes as multidrug carrier of resveratrol and 5-fluorouracil for their topical delivery. Int. J. Pharm. 489 (2015), 1–10.
165. Schuster, R., Holzer, W., Doerfler, H., Weckwerth, W., Viernstein, H., Okonogi, S., Mueller, M., Cajanus cajan- a source of PPARγ activators leading to anti-inflammatory and cytotoxic effects. Food Funct. 7 (2016), 3798–3806.
166. López-Nicolás, J.M., García-Carmona, F., Rapid: simple and sensitive determination of the apparent formation constants of trans-resveratrol complexes with natural cyclodextrins in aqueous medium using HPLC. Food Chem. 109 (2008), 868–875.
167. López-Nicolás, J.M., Rodríguez-Bonilla, P., García-Carmona, F., Complexation of pinosylvin an analogue of resveratrol with high antifungal and antimicrobial activity, by different types of cyclodextrins. J. Agric. Food Chem. 57 (2009), 10175–10180.
168. López-Nicolás, J.M., Rodríguez-Bonilla, P., Méndez-Cazorla, L., García-Carmona, F., Physicochemical study of the complexation of pterostilbene by natural and modified cyclodextrins. J. Agric. Food Chem. 57 (2009), 5294–5300.
169. Lu, Z., Chen, R., Fu, R., Xiong, J., Hu, Y., Cytotoxicity and inhibition of lipid peroxidation activity of resveratrol/cyclodextrin inclusion complexes. J. Incl. Phenom. Macrocycl. Chem., 73, 2012, 313.
170. Venuti, V., Cannavà, C., Cristiano, M.C., Fresta, M., Majolino, D., Paolino, D., Stancanelli, R., Tommasini, S., Ventura, C.A., A characterization study of resveratrol/sulfobutyl ether-β-cyclodextrin inclusion complex and in vitro anticancer activity. Colloids Surf. B. Biointerfaces 115 (2014), 22–28.
171. Summerlin, N., Soo, E., Thakur, S., Qu, Z., Jambhrunkar, S., Popat, A., Resveratrol nanoformulations: challenges and opportunities. Int. J. Pharm. 479 (2015), 282–290.
172. Zhang, Y., Shang, Z., Gao, C., Du, M., Xu, S., Song, H., Liu, T., Nanoemulsion for solubilization stabilization, and in vitro release of pterostilbene for oral delivery. AAPS PharmSciTech 15 (2014), 1000–1008.
173. Qian, C., Decker, E.A., Xiao, H., McClements, D.J., Nanoemulsion delivery systems: influence of carrier oil on β-carotene bioaccessibility. Food. Chem. 135 (2012), 1440–1447.
174. Sirerol, J.A., Feddi, F., Mena, S., Rodriguez, M.L., Sirera, P., Aupí, M., Pérez, S., Asensi, M., Ortega, A., Estrela, J.M., Topical treatment with pterostilbene a natural phytoalexin, effectively protects hairless mice against UVB radiation-induced skin damage and carcinogenesis. Free Radic. Biol. Med. 85 (2015), 1–11.
175. Caddeo, C., Teskac, K., Sinico, C., Kristl, J., Effect of resveratrol incorporated in liposomes on proliferation and UV-B protection of cells. Int. J. Pharm. 363 (2008), 183–191.
176. Jøraholmen, M.W., Škalko-Basnet, N., Acharya, G., Basnet, P., Resveratrol-loaded liposomes for topical treatment of the vaginal inflammation and infections. Eur. J. Pharm. Sci. 79 (2015), 112–121.
177. Jeong, H., Samdani, K.J., Yoo, D.H., Lee, D.W., Kim, N.H., Yoo, I.S., Lee, J.H., Resveratrol cross-linked chitosan loaded with phospholipid for controlled release and antioxidant activity. Int. J. Biol. Macromol. 93 (2016), 757–766.
178. Poornima, B., Korrapati, P.S., Fabrication of chitosan-polycaprolactone composite nanofibrous scaffold for simultaneous delivery of ferulic acid and resveratrol. Carbohydr. Polym. 157 (2017), 1741–1749.
179. Zhang, Y., Shi, X., Yu, Y., Zhao, S., Song, H., Chen, A., Shang, Z., Preparation and characterization of vanillin cross-linked chitosan microspheres of pterostilbene. Int. J Polym.Anal. Ch. 19 (2014), 83–93.
180. Dhanapal, J., Ravindrran, M.B., Baskar, S.K., Toxic effects of aflatoxin B1 on embryonic development of zebrafish (Danio rerio): potential activity of piceatannol encapsulated chitosan/poly (lactic acid) nanoparticles. Anticancer Agents Med. Chem. 15 (2015), 248–257.
181. Jung, K.H., Lee, J.H., Park, J.W., Quach, C.H., Moon, S.H., Cho, Y.S., Lee, K.H., Int. J. Pharm. 478 (2015), 251–257.
182. Li, J., Zhao, L.H., Huang, X., Liu, L., Zhang, Z.Z., Chen, Y.X., Ren, C.P., Gong, L., Polyethyleneglycol-modified poly(d,l-lactideco-glycolide) loaded resveratrol nanoparticles characterization and their anti-cancer activities. J. Nanosci. Nanotechno. 16 (2016), 9477–9481.
183. Penalva, R., Esparza, I., Larraneta, E., González-Navarro, C.J., Gamazo, C., Irache, J.M., Zein-based nanoparticles improve the oral bioavailability of resveratrol and its anti-inflammatory effects in a mouse model of endotoxic shock. J. Agric. Food Chem. 63 (2015), 5603–5611.
184. Huang, X., Dai, Y., Cai, J., Zhong, N., Xiao, H., McClements, D.J., Hu, K., Resveratrol encapsulation in core-shell biopolymer nanoparticles: impact on antioxidant and anticancer activities. Food Hydrocolloids 64 (2017), 157–165.
185. Mukherjee, S., Ray, S., Thakur, R.S., Solid lipid nanoparticles: a modern formulation approach in drug delivery system. Indian J. Pharm. Sci. 71 (2009), 349–358.
186. Teskac, K., Kristl, J., The evidence for solid lipid nanoparticles mediated cell uptake of resveratrol. Int. J. Pharm. 390 (2010), 61–69.
187. Jose, S., Anju, S.S., Cinu, T.A., Aleykutty, N.A., Thomas, S., Souto, E.B., In vivo pharmacokinetics and biodistribution of resveratrol-loaded solid lipid nanoparticles for brain delivery. Int. J. Pharm. 474 (2014), 6–13.
188. Neves, A.R., Lúcio, M., Martins, S., Lima, J.L., Reis, S., Novel resveratrol nanodelivery systems based on lipid nanoparticles to enhance its oral bioavailability. Int. J. Nanomed. 8 (2013), 177–187.
189. Pandita, D., Kumar, S., Poonia, N., Lather, V., Solid lipid nanoparticles enhance oral bioavailability of resveratrol a natural polyphenol. Food Res. Int. 62 (2014), 1165–1174.
190. Ahmad, I., Anwar, M., Akhter, S., Thakur, P., Chawla, R., Sharma, R.K., Ali, A., Ahmad, F.J., Supercritical fluid technology-based trans-resveratrol SLN for long circulation and improved radioprotection. J. Pharm. Innov. 11 (2016), 308–322.
191. Carlotti, M.E., Sapino, S., Ugazio, E., Gallarate, M., Morel, S., Resveratrol in solid lipid nanoparticles. J. Dispersion Sci. Technol. 33 (2012), 465–471.
192. Koeberle, A., Werz, O., Multi-target approach for natural products in inflammation. Drug Discov. Today 19 (2014), 1871–1882.
193. Chow Garland, H.H.L.L., Hsu, C.H., Vining, D.R., Chew, W.M., Miller, J.A., Perloff, M., Crowell, J.A., Alberts, D.S., Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev. Res. (Phila) 3 (2010), 1168–1175.